Zihua Zou

9PUBLICATIONS
41CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Mar 20, 2026
TP53 CpG Site Mutations Predict the Survival of First-Line Chemoimmunotherapy in Advanced Lung Adenocarcinoma.

Lige Wu, Zihua Zou, Yan Li

|Feb 09, 2026
Efficacy and safety of lorlatinib in first-line and subsequent-line treatments for patients with ALK-positive non-small cell lung cancer: a single-center real-world study in China.

Lige Wu, Jiayu Liu, Zihua Zou

|Jun 08, 2025
Chinese Expert Consensus on Leptomeningeal Metastases of Lung Cancer.

Gen Lin, Yongsheng Wang, Tao Xin

|May 12, 2025
A Real-World Study: Therapeutic Outcomes of ROS1-Positive Advanced NSCLC.

Hanqi Yuan, Zihua Zou, Xuezhi Hao

|Jan 22, 2025
Impact of EML4-ALK Variants and TP53 Status on the Efficacy of ALK Inhibitors in Patients With Non-small Cell Lung Cancer.

Zihua Zou, Lige Wu, Xuezhi Hao

|Jan 14, 2024
Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer.

Gen Lin, Zhijie Wang, Qian Chu

Pageof 2

Frequent Collaborators

6 joint publications

Puyuan Xing

5 joint publications

Junling Li

3 joint publications

Lige Wu

2 joint publications

Chengzhi Zhou